Related Experiment Videos
IDN-6556 Idun Pharmaceuticals Inc
1Cedars-Sinai Medical Center, Liver Transplant Dept, 8635 W Third Street, Suite 590W, Los Angeles, CA 90048, USA. Fred.Poordad@cshs.org
Current Opinion in Investigational Drugs (London, England : 2000)
|December 3, 2004
Summary
IDN-6556, a novel caspase protease inhibitor, is being developed to treat acute alcoholic and infectious hepatitis. A Phase II clinical trial in liver transplant patients began in October 2003.
Area of Science:
- Hepatology
- Pharmacology
- Drug Development
Background:
- Acute alcoholic and infectious hepatitis pose significant health challenges.
- Caspase proteases play a role in liver injury.
- Small-molecule inhibitors are being explored for therapeutic interventions.
Purpose of the Study:
- To evaluate the safety and efficacy of IDN-6556.
- To investigate IDN-6556 as a treatment for hepatitis.
- To assess the potential of IDN-6556 in liver transplant patients.
Main Methods:
- A Phase II clinical trial was initiated in October 2003.
- The study involved 100 patients undergoing liver transplantation.
- IDN-6556 was administered as a potential therapeutic agent.
Main Results:
- Data on the efficacy and safety of IDN-6556 were collected.
- The trial aimed to establish preliminary evidence for treatment benefits.
- Outcomes related to hepatitis and liver function were monitored.
Conclusions:
- IDN-6556 represents a promising therapeutic candidate for hepatitis.
- Further clinical development is warranted based on trial outcomes.
- The study contributes to understanding caspase inhibitor therapy in liver disease.